Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04492293 | An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer | unknown | Phase 2 | 115 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY |
| 1 |
| Feb 26, 2024 |
| clinicaltrials |
| NCT05297552 | A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05975151 | Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 63 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06009848 | Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT04543110 | Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC(RADIANT) | unknown | Phase 2 | 16 | Ottawa Hospital Research InstituteOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT04799847 | Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | unknown | Phase 1 / Phase 2 | 161 | LintonPharm Co.,Ltd.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05445648 | Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer(CBPTMI) | unknown | Phase 2 | 65 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT03529890 | Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder(RACE IT) | unknown | Phase 2 | 33 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT04784507 | En-Bloc Resection of Bladder Tumors | unknown | Phase 2 | 60 | Betul KartalOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)(NURE-Combo) | unknown | Phase 2 | 29 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03759496 | Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 39 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03993249 | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | unknown | Phase 2 | 78 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03762161 | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | unknown | Phase 2 | 22 | Rahul ParikhOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05016973 | A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer | unknown | Phase 2 | 25 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT05001763 | Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy | unknown | Phase 2 | 160 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Aug 12, 2021 | clinicaltrials |
| NCT04922047 | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)(TACBIN-01) | unknown | Phase 1 / Phase 2 | 6 | RenJi HospitalOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04878250 | Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder(PEBBLE) | unknown | Phase 2 | 49 | Queen Mary University of LondonOTHER | 0 | May 7, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04738630 | Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer | unknown | Phase 2 | 110 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04493489 | Propranolol Adjuvant Treatment of Bladder Cancer | unknown | Phase 2 | 242 | Central South UniversityOTHER | 0 | Jul 30, 2020 | clinicaltrials |
| NCT04219046 | Evaluation of Naloxegol in the Prevention of POI After Cystectomy(ANTAGOCYST) | unknown | Phase 2 | 102 | Institut Paoli-CalmettesOTHER | 0 | Jul 28, 2020 | clinicaltrials |
| NCT02070120 | Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer(CALIBER) | unknown | Phase 2 | 82 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04060459 | Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 50 | Third Military Medical UniversityOTHER | 1 | Aug 19, 2019 | clinicaltrials |
| NCT03982797 | Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis | unknown | Phase 2 | 306 | Biofabri, S.LINDUSTRY | 1 | Jun 12, 2019 | clinicaltrials |
| NCT02805608 | uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer | unknown | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Apr 11, 2018 | clinicaltrials |
| NCT03427034 | Assessment of BladderLight SurvEILlance(ABSEIL) | unknown | Phase 2 / Phase 3 | 2,100 | Cambridge University Hospitals NHS Foundation TrustOTHER | 0 | Feb 9, 2018 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02360618 | Metformin and Simvastatin Use in Bladder Cancer | unknown | Phase 2 | 44 | London Health Sciences CentreOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT02422277 | Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy | unknown | Phase 2 | 60 | Mansoura UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00949455 | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium(LaMB) | unknown | Phase 2 / Phase 3 | 204 | Queen Mary University of LondonOTHER | 1 | Apr 15, 2015 | clinicaltrials |
| NCT02345499 | Open Versus Laparoscopic Radical Cystectomy(OvsL) | unknown | Phase 2 | 80 | Azienda Ospedaliero-Universitaria Consorziale Policlinico di BariOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00005958 | Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer | unknown | Phase 2 | — | AmgenINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT01222676 | Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder | unknown | Phase 2 | 45 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Aug 12, 2013 | clinicaltrials |
| NCT01118039 | Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer | unknown | Phase 2 | 41 | Hospital del MarOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00633204 | Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer | unknown | Phase 2 | 150 | Iwate Medical UniversityOTHER | 1 | Jun 23, 2011 | clinicaltrials |
| NCT01196403 | Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | unknown | Phase 2 | 92 | Wales Cancer Trials UnitOTHER | 1 | Apr 1, 2011 | clinicaltrials |
| NCT01000129 | Adaptive Planning in Bladder Cancer(APPLY) | unknown | Phase 2 | 32 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 22, 2009 | clinicaltrials |
| NCT00816075 | Efficacy of Distilled Water Versus Mitomycin C on Preventing Recurrences of Bladder Cancer After Transurethral Resection | unknown | Phase 2 / Phase 3 | 40 | Bozyaka Training and Research HospitalOTHER | 1 | Feb 17, 2009 | clinicaltrials |
| NCT00818350 | Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer | unknown | Phase 1 / Phase 2 | 25 | Campania Younger Oncologists AssociationOTHER | 0 | Jan 7, 2009 | clinicaltrials |
| NCT00006118 | Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer | unknown | Phase 2 | — | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 2 | Jul 24, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Mar 6, 2024source: clinicaltrials